Publication | Closed Access

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Neoadjuvant DurvalumabOncologyRadiation TherapyRandomised Phase 2Cancer TreatmentStereotactic Body RadiotherapyMedicineRadiation OncologyLung Cancer